RxDoctor Payments Data

Gary Ullery

Internal Medicine · Blackfoot, IDNPI 1164785382

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,879 of the $2,734 with a category attached, or 68.7%. Modernatx, Inc. accounts for 80.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $2,349 and has fallen 98.8% since, to $27 in 2025. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,734in general payments, 2019–2025

Across 39 payments — averaging $70.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$2K
  • GSK$64
  • Medtronic$55
  • Abbott$43
  • Novo Nordisk$38
  • Biohaven Pharmaceuticals, Inc.$38
  • plus $285 from 15 others
$1,689,047in research payments, 2019–2025

Across 94 payments — averaging $17,969 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$839K
  • Sanofi Pasteur Inc.$494K
  • Eli Lilly$185K
  • Merck$168K
  • Eli Lilly Export S.A. Puerto Rico Branch$3K

What the payments were for

  • Travel & lodging$1,87969%
  • Food & beverage$85531%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,734 in reported general payments places this provider in the 90th percentile of 289 internal medicine providers in Idaho.

See all internal medicine providers in Idaho

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$45,287
EliquisApixaban41$29,075
VraylarCariprazine Hcl13$18,909
MounjaroTirzepatide16$15,887
Tresiba Flextouch U-100Insulin Degludec13$7,135
GemtesaVibegron13$5,759
Advair HfaFluticasone Propion/Salmeterol12$5,378
Atomoxetine Hcl15$3,932
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,889
Celecoxib54$2,540
Apidra SolostarInsulin Glulisine14$2,350
Testosterone Cypionate23$2,218
Omeprazole110$1,548
Buspirone Hcl34$1,063
Gabapentin97$1,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$38$45,28749 claims
PfizerEliquis$12$29,07541 claims
AbbVieVraylar$15$18,90913 claims
Lilly USA, LLCMounjaro$30$15,88716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 internal medicine providers in Idaho.

Other internal medicine in Blackfoot

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →